Time to next treatment: IVA-IVB disease. OS of patients with advanced-stage disease according to presence (n = 22) or absence (n = 70) of LCT in the advanced-stage population.¹⁵  Median OS in the transformed group was 2.2 years, compared with 5.2 years in the nontransformed group. TTNT, time to next treatment.